• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $EQRX

    EQRx Inc.

    Subscribe to $EQRX
    $EQRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: https://www.eqrx.com

    Recent Analyst Ratings for EQRx Inc.

    DatePrice TargetRatingAnalyst
    11/14/2022Neutral → Underweight
    JP Morgan
    11/11/2022$8.00 → $5.00Buy → Neutral
    Goldman
    11/11/2022$5.60 → $3.20Buy → Hold
    Jefferies
    8/16/2022$5.50Neutral
    JP Morgan
    6/13/2022$8.00Buy
    Goldman
    4/22/2022Outperform
    Cowen
    3/18/2022$5.60Buy
    Jefferies
    See more ratings

    EQRx Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nallicheri Melanie returned 10,157,393 shares to the company and exercised 626,999 shares at a strike of $2.21, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:27:28 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Merksamer Samuel J.

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:18:02 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berns Paul L returned 627,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:18:04 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Horning Sandra returned 470,250 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:13:43 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ciarimboli Dina returned 731,750 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:13:24 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Yeshwant Krishna

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:12:09 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Conde Jorge returned 53,064,157 shares to the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:11:09 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Giusti Kathryn E

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:09:24 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Ah Equity Partners Lsv I, L.L.C.

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:06:10 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abernethy Amy returned 200,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:06:29 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care